Genitourinary Cancers Symposium (ASCO GU) | Conference

LuPSMA May Improve Survival in Heavily Pretreated mCRPC

February 12th 2019

The novel targeted radiation therapy lutetium-177 PSMA-617 showed strong clinical activity and the potential to improve survival in heavily pretreated men with PSMA-positive metastatic castration-resistant prostate cancer.

Pembrolizumab Plus Axitinib Active in Frontline RCC

February 12th 2018

Antitumor activity of the combination of axitinib (Inlyta) and pembrolizumab (Keytruda) is superior to that expected from axitinib or PD-1/PD-L1 pathway inhibitor monotherapy in treatment-naïve patients with advanced renal cell carcinoma.

Cabozantinib Proves Superior to Sunitinib in All Subgroups Examined in CABOSUN

February 12th 2018

Cabozantinib (Cabometyx) improved progression-free survival as initial systemic therapy across subgroups of patients with intermediate- and poor-risk advanced RCC enrolled in the randomized phase II CABOSUN trial.

Erdafitinib Elicits High Response Rates in FGFR-Positive Urothelial Cancer

February 11th 2018

Erdafitinib showed responses in more than one-third of patients with pretreated metastatic or unresectable FGFR alteration-positive urothelial carcinoma.

Dr. Slovin Discusses a Study Comparing Cardiovascular Events With Degarelix, Leuprolide in Prostate Cancer

February 11th 2018

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.

Pembrolizumab Survival Benefit Sustained in 2-Year Urothelial Cancer Data

February 10th 2018

Two-year follow-up data showed sustained improvements in overall survival with pembrolizumab over chemotherapy in pretreated patients with locally advanced or recurrent urothelial cancer.

Dr. Gulley Discusses a Phase II Study of Olaparib and Durvalumab in mCRPC

February 10th 2018

James Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service, at the National Cancer Institute, discusses a phase II study of olaparib (Lynparza) and durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer (mCRPC) in an unselected patient population, presented at the 2018 Genitourinary Cancers Symposium.

Dr. Bellmunt Discusses Follow-Up Data for Pembrolizumab vs Chemotherapy in Bladder Cancer

February 10th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses 2-year follow-up results from the phase III KEYNOTE-045 trial of pembrolizumab (Keytruda) versus chemotherapy in recurrent, advanced urothelial carcinoma during the 2018 Genitourinary Cancers Symposium.

Dr. Sonpavde on Fixed-Dose Durvalumab and Tremelimumab Study in Urothelial Carcinoma

February 10th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a phase IIIb safety study of fixed-dose durvalumab (Imfinzi) and tremelimumab in patients with advanced urothelial carcinoma.

SM-88 Delays Recurrence for Nonmetastatic Prostate Cancer

February 9th 2018

Data from the first 13 evaluable patients enrolled in a phase II study of SM-88 showed a reduction in circulating tumor cells, a slowing of prostate-specific antigen increase, and delayed radiographic progression of disease in nonmetastatic prostate cancer.

Olaparib/Durvalumab Combo Shows Promise in mCRPC

February 9th 2018

The PARP inhibitor olaparib appeared to complement the antitumor activity of the PD-L1 inhibitor durvalumab in unselected men with metastatic castrate-resistant prostate cancer, according to findings from a phase II study presented at the 2018 Genitourinary Cancers Symposium.

Dr. Plimack Discusses Trials Investigating Apalutamide, Enzalutamide in M0 CRPC

February 9th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses 2 studies reported at the 2018 Genitourinary Cancers Symposium in patients with nonmetastatic M0 castration-resistant prostate cancer (CRPC).

Dr. Joshi Discusses Durvalumab and Radiation Therapy in Bladder Cancer

February 9th 2018

Monika Joshi, MD, assistant professor, Penn State Hershey Medical Center, discusses a phase Ib study of durvalumab (Imfinzi) and radiation therapy (DUART) followed by adjuvant durvalumab in patients with urothelial carcinoma.

New Model Predicts Survival Following Treatment With Atezolizumab for Bladder Cancer

February 6th 2018

A new model based on 6 clinical factors may be able to predict overall survival for patients with advanced urothelial cancers being treated with the PD-L1 inhibitor atezolizumab.

Docetaxel Adds to QALY in Advanced Prostate Disease

February 6th 2018

The addition of docetaxel (Taxotere) to frontline long-term hormone therapy for advanced prostate cancer improved quality of life and reduced the need for subsequent therapy, contributing to lower overall costs in the nonmetastatic setting.

Apalutamide Delays Metastasis by Over 2 Years in Prostate Cancer

February 6th 2018

Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer, according to findings from the phase III SPARTAN trial.

Atezolizumab Combo Improves PFS by 3.5 Months in mRCC

February 6th 2018

The combination of atezolizumab and bevacizumab reduced the risk of progression or death by 26% compared with sunitinib for patients with untreated PD-L1–positive metastatic renal cell carcinoma.

Enzalutamide More Than Doubles MFS for Nonmetastatic CRPC

February 6th 2018

Treatment with the combination of enzalutamide and androgen deprivation therapy reduced the risk of metastases or death by 71% compared with ADT alone in patients with nonmetastatic castration-resistant prostate cancer.

Josh Armenia on Impact of Mutated Gene Analysis in Prostate Cancer

February 22nd 2017

Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the impact of a gene mutation analysis study in prostate cancer.

Vogelzang Emphasizes Aggressive Biopsies, Novel Therapies in Urothelial Carcinoma

February 21st 2017

At the 2017 Genitourinary Cancers Symposium, Nicholas J. Vogelzang, MD, discussed diagnostic practices and emerging therapies in the field of bladder cancer.